- The FDA has approved Sanofi SA’s (NASDAQ:SNY) newly completed plant in Swiftwater, Pennsylvania.
- The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.
- With $425 million of investment, the opening of the new plant will require Sanofi to add up to 200 employees.
- Fluzone High-Dose is a quadrivalent vaccine targeting four flu strains.
- Price Action: SNY shares are down 0.43% at $53.19 during the market trading session on the last check Thursday.
Needham Maintains Buy on Skyworks Solutions, Lowers Price Target to $130
Needham analyst Rajvindra Gill maintains Skyworks Solutions (NASDAQ:SWKS) with a Buy and lowers the price target from $255 to $130.
